187 related articles for article (PubMed ID: 37625037)
41. Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice.
Luan N; Cao H; Wang Y; Lin K; Hu J; Liu C
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376650
[TBL] [Abstract][Full Text] [Related]
42. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
43. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant.
Zhang N; Ji Q; Liu Z; Tang K; Xie Y; Li K; Zhou J; Li S; Shang H; Shi Z; Zheng T; Yao J; Lu L; Yuan S; Jiang S
Viruses; 2022 Feb; 14(3):. PubMed ID: 35336907
[TBL] [Abstract][Full Text] [Related]
44. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
45. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
[TBL] [Abstract][Full Text] [Related]
46. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Buntinx E; Brochado L; Borja-Tabora C; Yu CY; Alberto ER; Montellano MEB; Carlos JC; Toloza LB; Hites M; Siber G; Clemens R; Ambrosino D; Qin H; Chen HL; Han HH; Hu B; Li P; Baccarini C; Smolenov I
Vaccine; 2023 Mar; 41(11):1875-1884. PubMed ID: 36781334
[TBL] [Abstract][Full Text] [Related]
48. Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
Shen X; Hao Y; Wang S; Li D; Ren L; Zhu M; Wang S; Li J; Tang W; Fu Y; Chen R; Liu Y; Shao Y
Vaccine; 2023 Oct; 41(45):6645-6653. PubMed ID: 37770297
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
Zhang T; Wang Z; Yang J; Xu X
J Med Virol; 2023 Feb; 95(2):e28563. PubMed ID: 36755368
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
Front Immunol; 2022; 13():939311. PubMed ID: 36032136
[TBL] [Abstract][Full Text] [Related]
51. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.
Sui Y; Andersen H; Li J; Hoang T; Bekele Y; Kar S; Lewis MG; Berzofsky JA
Front Immunol; 2023; 14():1154496. PubMed ID: 37020550
[TBL] [Abstract][Full Text] [Related]
52. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
53. Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls.
Wang S; Li J; Wang S; Ye Y; Li M; Liu Y; Chen B; Lai Y; Li L; Zhuang L; Peng S; Yang N; Zhang H; Xiao H
Clin Transl Med; 2023 Jan; 13(1):e1171. PubMed ID: 36639826
[TBL] [Abstract][Full Text] [Related]
54. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.
Gray LT; Raczy MM; Briquez PS; Marchell TM; Alpar AT; Wallace RP; Volpatti LR; Sasso MS; Cao S; Nguyen M; Mansurov A; Budina E; Watkins EA; Solanki A; Mitrousis N; Reda JW; Yu SS; Tremain AC; Wang R; Nicolaescu V; Furlong K; Dvorkin S; Manicassamy B; Randall G; Wilson DS; Kwissa M; Swartz MA; Hubbell JA
Biomaterials; 2021 Nov; 278():121159. PubMed ID: 34634664
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Dillard JA; Taft-Benz SA; Knight AC; Anderson EJ; Pressey KD; Parotti B; Martinez SA; Diaz JL; Sarkar S; Madden EA; De la Cruz G; Adams LE; Dinnon KH; Leist SR; Martinez DR; Schäfer A; Powers JM; Yount BL; Castillo IN; Morales NL; Burdick J; Evangelista MKD; Ralph LM; Pankow NC; Linnertz CL; Lakshmanane P; Montgomery SA; Ferris MT; Baric RS; Baxter VK; Heise MT
Nat Commun; 2024 May; 15(1):3738. PubMed ID: 38702297
[TBL] [Abstract][Full Text] [Related]
56. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
57. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
58. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
Takasuka N; Fujii H; Takahashi Y; Kasai M; Morikawa S; Itamura S; Ishii K; Sakaguchi M; Ohnishi K; Ohshima M; Hashimoto S; Odagiri T; Tashiro M; Yoshikura H; Takemori T; Tsunetsugu-Yokota Y
Int Immunol; 2004 Oct; 16(10):1423-30. PubMed ID: 15314040
[TBL] [Abstract][Full Text] [Related]
59. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
60. A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants.
Liu Y; Zhao D; Wang Y; Chen Z; Yang L; Li W; Gong Y; Gan C; Tang J; Zhang T; Tang D; Dong X; Yang Q; Valencia CA; Dai L; Qi S; Dong B; Chow HY; Li Y
Front Immunol; 2022; 13():1011484. PubMed ID: 36439096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
